If you would like more information about the profile please click
. You will be directed to a new page where you will need
to provide some information about yourself/your business cooperation needs and submit
your expression of interest in the profile . A Network Partner will then contact
you to discuss your interest in greater detail.
The French TTO (technology transfer office) is acting on behalf of major hospital and research group of the Paris region that offers a new gel for the treatment of burns due to the hydrofluoric acid.
The French public research centre is looking for a technical cooperation or a license agreement.
A French clinical research team has developed a new method to minimize the chemical burn. This research team is represented by a Technology Transfer Office (TTO) established more than 20 years ago.The TTO is responsible for protecting and leveraging the intellectual property generated by a major hospital group in the Paris region. It aims to create the best conditions to bring to market innovative products and services directly from hospital care and clinical research.
Hydrofluoric acid is present in various domestic products. Hydrofluoric acid can cause serious and painful burns on the skin and eyes, erythema or even development of necrosis and bone decalcification.
Calcium gluconate-based infiltrations or gel have been used for a long time to treat effectively hydrofluoric acid severe burns. However, this gel is only available in magistral preparation form gel and is not marketed by pharmaceutical laboratories. The absence of standardization of the preparation of this gel, and also the absence of stability and sterility tests, represent significant limiting factors for these products although their effectiveness has been demonstrated.
The invention relates to a calcium gluconate-based formulation advantageously capable of being sprayed in liquid form on the burn and instantaneously gelling when in contact with the skin. Compared with a solution, the presence of a gel texture at the surface of the skin enables extended contact of the calcium gluconate with the injury.
The partner sought could be a company interested in :
- a license agreement as the TTO is ready to negociate directly the patents rights for specific applications, or
- a technical cooperation agreement.
The main advantages are :
-easy to apply and can be widely spread on the burns
-easy to prepare and package in order to be stored under sterile conditions
-particularly stable over time and can be stored for several months.
This formulation makes also it possible to give first aid rapidly, safely and economically in the case of accidental hydrofluoric acid burns
The formulation is finalized and has been tested in vitro. The packaging must be validated.
Patents granted in France, Canada, Israël, United-States and in Europe.
The requested partner may be any medical device or pharmaceutical company (SME or large firm).
The partner sought could be a company interested in the licence of the patent (under a license agreement) and interested in the know-how of this platform (under a technical cooperation agreement).
The partner sought should launch the CE marking of this medical device (this product cannot be regarded as a drug) and commercialize this solgel.
The Technology Transfer Office (TTO) action on behalf the research team, is responsible for protecting and leveraging the intellectual property from large university hospitals.